事件公司发布2024 年年度业绩。公司总收入达94.2 亿元人民币，同比增长51.8%；产品收入82.3 亿元，同比增长43.6%。公司首次实现Non-IFRS 利润转正（3.3 亿元）及EBITDA 转正（4.1 亿元），IFRS 亏损同比收窄90.8%。授权收入约11 亿元，其中6.9 亿元来自与驯鹿生物关于福可苏?（伊基奥仑赛注射液）的全球商业化权益及知识产权许可等权益转让。各项费用率均下降...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.